Red cell membrane during erythropoietin therapy in hemodialysis and in hemodiafiltration.
This study assessed the effect of recombinant human erythropoietin (r-HuEPO) on red cell membrane behaviour in patients undergoing hemodialysis (HD) and hemodiafiltration (HDF). We studied erythrocyte osmotic fragility (EOF), mechanical fragility (EMF) and deformability (ED) before and after r-HuEPO therapy in patients on conventional dialysis treatment with a cuprophan membrane and in subjects undergoing HDF with a polyacrylonitrile membrane. Non-uremic, non-anemic subjects were enrolled as controls. Red cell membrane defects were more evident in HD than in HDF; r-HuEPO seemed to improve deformability in both groups compared to controls (p less than 0.005) possibly through the great production of red cells during this therapy.
Icardi
A
A
Division of Nephrology and Dialysis, San Martino Hospital, Genova, Italy.
Paoletti
E
E
Traverso
G B
GB
Sarchi
C
C
Cappelli
G
G
Molinelli
G
G
D000740:Anemia / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D004907:Erythrocyte Deformability / Q000502:physiology; D004910:Erythrocyte Membrane / Q000502:physiology*; D004921:Erythropoietin / Q000627:therapeutic use*; D005260:Female; D006440:Hemofiltration; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications / Q000628:therapy; D008297:Male; D008567:Membranes, Artificial; D008875:Middle Aged; D009996:Osmotic Fragility / Q000502:physiology; D011994:Recombinant Proteins / Q000627:therapeutic use; D006435:Renal Dialysis
D008567:Membranes, Artificial; D011994:Recombinant Proteins; D004921:Erythropoietin